"H2 npat at mid point up 33% on pcp, HY was up 7%. "...

"H2 npat at mid point up 33% on pcp, HY was up 7%. "

@CaptainBarnacles,

I'd be a bit wary of using the NPAT line as a measure of KME's underlying financial performance. The reason I say that is because the JH2017 result was boosted by a very light tax rate (12.8%), although this was partly offset of a doubling in the D&A charge on pcp (from $230k to $470k).

The cleaner picture, I think, is obtained at looking at the EBITDA line, where the first half was up 22% (to $1.448m in DH2017 from DH2016's $1.190m), and the mid-point of today's full-year EBITDA guidance implies a 42% increase in the second-half (to $2.05m, from $1.445m in JH2017).
.